Scholarlink

Background <p>Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is an established cardiac physiologic pacing strategy for patients requiring substantial ventricular pacing, heart failure (HF), and reduced left ventricular ejection fraction (LVEF). Recently, left bundle branch area pacing (LBBAP) has emerged as a promising alternative to BVP. It remains uncertain whether BVP or LBBAP is more advantageous for patients with mild-to-moderately reduced left ventricular systolic function.</p> Objective <p>To compare efficacy and safety of LBBAP and BVP in patients with atrioventricular block and LVEF of 36-50%.</p> Methods <p>The BLOCK NAGOYA trial is a multicenter, prospective, randomized, controlled trial to determine whether LBBAP is superior to BVP in terms in improving left ventricular function. A total of 46 participants, with advanced atrioventricular block, HF, and LVEF of 36-50%, will be recruited in 17 Japanese institutions and randomized to receive either LBBAP (with targeted left bundle branch capture) or BVP treatment arm.</p> Results <p>The primary endpoint is the change in LVEF at 6 months. Secondary endpoints include changes in brain natriuretic peptide levels, electrocardiographic and echocardiographic findings at 6 months, clinical outcomes (hospitalization for HF or ventricular arrhythmias), and adverse events. The follow-up duration is set to two years after the implantation.</p> Conclusion <p>The BLOCK NAGOYA trial will provide significant insights on the optimal physiologic pacing therapy for patients with atrioventricular block, HF, and mild-to-moderately reduced LVEF.</p> Trial registration number <p>Japan Registry of Clinical Trials: jRCTs042240129: <a href="https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240129">https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240129</a></p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison of left bundle branch area pacing and biventricular pacing for atrioventricular block with heart failure and mild-to-moderately reduced left ventricular systolic function: design and rationale of the BLOCK NAGOYA randomized clinical trial

  • 期刊论文

  • 发表日期：

    2026年1月2日

查看全文
  • Hiroyuki Kato,
  • Satoshi Yanagisawa,
  • Itsuro Morishima,
  • Yasunori Kanzaki,
  • Hirohiko Suzuki,
  • Nobuhiro Takasugi,
  • Koyo Sato,
  • Shunichiro Warita,
  • Yoshihisa Naruse,
  • Kenichiro Yokoi,
  • Shinji Ishikawa,
  • Shinya Sugiura,
  • Yoshiaki Mizutani,
  • Yosuke Kamikubo,
  • Takayuki Goto,
  • Yosuke Murase,
  • Yusuke Sakamoto,
  • Daisuke Yoshimoto,
  • Junya Funabiki,
  • Yachiyo Kuwatsuka,
  • Masahiko Ando,
  • Takahiro Okumura,
  • Yasuya Inden,
  • Toyoaki Murohara,
  • Taku Sakurai,
  • Ryusuke Ota,
  • Kazumasa Suga,
  • Keita Mamiya,
  • Hajime Imai,
  • Takashi Okajima,
  • Koichi Furui,
  • Tadahiro Ito,
  • Yutaro Kaneko,
  • Taro Narumi,
  • Makoto Sano,
  • Yoshitake Oshima,
  • Ryo Watanabe,
  • Monami Ando,
  • Yasuhiro Ogura,
  • Yuichiro Makino,
  • Yoshio Takemoto,
  • Yuko Uemura,
  • Ryo Yamaguchi,
  • Hirokazu Naganawa,
  • Yuichiro Sakamoto,
  • Masafumi Shimojo,
  • Yukiomi Tsuj

摘要

Background

Cardiac resynchronization therapy (CRT) with biventricular pacing (BVP) is an established cardiac physiologic pacing strategy for patients requiring substantial ventricular pacing, heart failure (HF), and reduced left ventricular ejection fraction (LVEF). Recently, left bundle branch area pacing (LBBAP) has emerged as a promising alternative to BVP. It remains uncertain whether BVP or LBBAP is more advantageous for patients with mild-to-moderately reduced left ventricular systolic function.

Objective

To compare efficacy and safety of LBBAP and BVP in patients with atrioventricular block and LVEF of 36-50%.

Methods

The BLOCK NAGOYA trial is a multicenter, prospective, randomized, controlled trial to determine whether LBBAP is superior to BVP in terms in improving left ventricular function. A total of 46 participants, with advanced atrioventricular block, HF, and LVEF of 36-50%, will be recruited in 17 Japanese institutions and randomized to receive either LBBAP (with targeted left bundle branch capture) or BVP treatment arm.

Results

The primary endpoint is the change in LVEF at 6 months. Secondary endpoints include changes in brain natriuretic peptide levels, electrocardiographic and echocardiographic findings at 6 months, clinical outcomes (hospitalization for HF or ventricular arrhythmias), and adverse events. The follow-up duration is set to two years after the implantation.

Conclusion

The BLOCK NAGOYA trial will provide significant insights on the optimal physiologic pacing therapy for patients with atrioventricular block, HF, and mild-to-moderately reduced LVEF.

Trial registration number

Japan Registry of Clinical Trials: jRCTs042240129: https://jrct.mhlw.go.jp/en-latest-detail/jRCTs042240129

Graphical Abstract